BHCM
RVNC

Brevan Howard Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Brevan Howard Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-522,716
Closed -$2.71M – 1515
2024
Q3 		$2.71M Buy
522,716
+483,448
+1,231% +$2.4M 0.02% 215
2024
Q2 		$101K Buy
+39,268
New +$134K ﹤0.01% 967
2024
Q1 		– Sell
-27,111
Closed -$238K – 1406
2023
Q4 		$238K Buy
+27,111
New +$222K ﹤0.01% 814

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Brevan Howard Capital Management's RVNC Position: Q4 2024 in Review

Brevan Howard Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 522,716 shares — an estimated $2.71M sold.

Brevan Howard Capital Management first reported a position in RVNC in Q4 2023 and held it in 3 quarters. The position peaked at $2.71M in Q3 2024. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Brevan Howard Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 522,716 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $2.71M.
  • Brevan Howard Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2023 and held it in 3 quarters.
  • Brevan Howard Capital Management's Revance Therapeutics, Inc. position peaked at $2.71M in Q3 2024.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Brevan Howard Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.